Zymeworks Inc. (NYSE:ZYME) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), both competing one another are Biotechnology companies. We will contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ZIOPHARM Oncology Inc.||N/A||4427.73||137.25M||-0.54||0.00|
In table 1 we can see Zymeworks Inc. and ZIOPHARM Oncology Inc.’s top-line revenue, earnings per share and valuation.
Table 2 shows us Zymeworks Inc. and ZIOPHARM Oncology Inc.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ZIOPHARM Oncology Inc.||0.00%||58.6%||-89.9%|
Zymeworks Inc.’s Current Ratio is 6.4 while its Quick Ratio is 6.4. On the competitive side is, ZIOPHARM Oncology Inc. which has a 0.8 Current Ratio and a 0.8 Quick Ratio. Zymeworks Inc. is better positioned to pay off short and long-term obligations compared to ZIOPHARM Oncology Inc.
Zymeworks Inc. and ZIOPHARM Oncology Inc. Recommendations and Ratings are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|ZIOPHARM Oncology Inc.||0||0||3||3.00|
Meanwhile, ZIOPHARM Oncology Inc.’s consensus price target is $6, while its potential upside is 50.00%.
Insider & Institutional Ownership
Zymeworks Inc. and ZIOPHARM Oncology Inc. has shares held by institutional investors as follows: 40.3% and 39.8%. 10.3% are Zymeworks Inc.’s share held by insiders. Competitively, ZIOPHARM Oncology Inc. has 1.7% of it’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|ZIOPHARM Oncology Inc.||-12.58%||20.98%||-25.14%||-3.9%||-25.14%||44.92%|
For the past year Zymeworks Inc. was less bullish than ZIOPHARM Oncology Inc.
On 6 of the 10 factors ZIOPHARM Oncology Inc. beats Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companyÂ’s lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Celgene Corporation and Celgene Alpine Investment Co. LLC, GlaxoSmithKline Intellectual Property Development Limited, and Daiichi Sankyo Co., Ltd. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.